20Jan 2017

IMMUNOHISTOCHEMICAL EXPRESSION OF GLUT-1 IN EPITHELIAL OVARIAN TUMORS: CORRELATION WITH THE CLINICOPATHOLOGICAL FACTORS AND TUMOR PROLIFERATIVE MARKER PCNA.

  • Pathology Department, Faculty of medicine, Zagazig University, Egypt.
  • Obstetrics and Gynecology Department, Faculty of medicine, Zagazig University, Egypt.
  • Surgery Department, Faculty of medicine, Zagazig University, Egypt.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: Ovarian carcinomas are frequently diagnosed at advanced-stage due to lack of distinct symptoms and reliable procedure for early detection. The applying of immunohistochemistry has become an important tool improving the prognosis of patients with ovarian carcinomas. Aim: To assess the expression of Glut-1 in epithelial ovarian tumors and study its correlation with PCNA to detect their usefulness in the diagnosis and prognosis of such tumors. Methods: Glut-1 immunoexpression was analyzed and correlated with PCNA in 45 epithelial ovarian tumors (7 benign, 10 borderline and 28 malignant tumors) Results: Glut-1 was expressed in 80% and 92.85% of the studied borderline and invasive carcinomas respectively, but not expressed in any benign tumors. These differences in Glut-1 expression among the benign, borderline and malignant cases, were statistically significant (p= 0.000). Analysis of Glut-1 immunoexpression with the clinicopathological criteria of ovarian carcinomas revealed that Glut-1 expression is moresignificantly expressed in high grade carcinoma and in tumors with an advanced FIGO stage (p=0.043 and p=0.005 respectively). Glut-1 was more significantly expressed in lymph node metastases positive group and in those with intraperitoneal implants (p=0.011 and 0.016 respectively).There was a strong positive significant correlation between Glut-1 and PCNA among the studied 45 ovarian tumors (Spearman correlation (r) = 0.603, p value= 0.000).Conclusion: Glut-1 can increase the diagnostic accuracy of ovarian tumors by help in differentiating between benign, borderline and malignant tumors. Glut-1 correlated with poor prognostic factors and can be used with PCNA as prognostic markers for epithelial ovarian tumors.


  1. Ibrahim, A., Khaled, H., Mikhail N., Baraka, H., Kamel, H. and Ibrahim, A.S. (2014): Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program. Journal of Cancer Epidemiology. 14-18.
  2. Daniel, G., Yang, G., Liu, G., Mercado-Uribe, I., Chang, B., Xiao, X., Zheng, J., Xue, F. and Liu, J. (2010): Ovarian cancer: pathology, biology, and disease models. Frontier in Bioscience. 14: 2089-2102.
  3. Parkin, D., Bray, F., Ferlay J. andPisani, P. (2005): Global cancer statistics. CA. Cancer J. Clin., 55: 74-108.
  4. Meinhold-Heerlein, I., Fotopoulou, C., Harter, P., Kurzeder, C., Mustea, A., Wimberger, P., Hauptmann, S. and Jalid Sehouli., S. (2016):The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications.Arch Gynecol Obstet., 293(4):695-700.
  5. Chi, D.S., Liao, J.B., Leon, L.F., Venkatraman, E.S., Hensley, M.L., Bhaskaran, D. and Hoskins, W.J. (2001): Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol. 82: 532?537.
  6. Ino, K., Shibata, K., H Kajiyama, H., E Yamamoto, E., T Nagasaka, T., A Nawa, A., S Nomura, S., and F Kikkawa, F. (2006): Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. British Journal of Cancer. 94: 552 ? 560.
  7. Tom?ov?, M. and Melichar, B. (2006): Contribution of immunohistochemistry in prognostic assessment of epithelial ovarian carcinoma. Acta Medica. 49(3): 161?165.
  8. McCluggage, W. (2006): Immunohistochemical and functional biomarkers of value in female genital tract lesions. International Journal of Gynecological Pathology. 25(2): 101-120.
  9. Coleman, R., Ramirez, P. and Gershenson, D. (2013): Neoplastic Diseases of the Ovary, Comprehensive Gynecology (6th ed.). Mosby. ISBN: 978-0-323-06986-1.
  10. Medina, R. and Owen, G. (2002): Glucose transporters: expression, regulation and cancer. BiolRes. 35(1):9?26.
  11. Wei, P., Jin, M., Zhao, H., Li X. and Diao, X.L. (2013): Expression of glucose transporter protein 1 and desmin in reactive mesothelial hyperplasia and epithelioid malignant mesothelioma.Cancer Cell, 42(7):451-454.
  12. Kim, S., Jung, W. and Koo, J. (2013): The Expression of Glut-1, CAIX, and MCT4 in Mucinous Carcinoma. J Breast Cancer.16 (2):146-151.
  13. Airley, R. and Mobasheri A. (2007): Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy, 53: 233-56.
  14. Carvalho, K., Cunha, W., Rocha, R.,Ayala, F., Caja?ba, M., Begnami, M., Vilela, R., Paiva, G., Andrade, R.,? and Soares, F. (2011): GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. CLINICS, 66 (6):965-972.
  15. Centuaria, G., Magalhaes, A., Penalver, M., Angioli, R, Braunschweiger, P. and Gomez-Marin, O. (2000): Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. Gynecol Oncol, 79: 33? 37.
  16. Cai, Y., Zhai, J., Feng, B., Duan, X., Z. and He, X.J. (2014): Expression of glucose transporter protein 1 and p63 in serous ovarian tumor, J. Obstet. Gynaecol. Res. 40 (7): 1925?1930.
  17. Younes, M, Lechago, L.V, Somoano, J.R, Mosharaf, M. and Lechago, J. (1996): Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res, 56:1164?7.
  18. Airley, R., Loncaster, J., Davidson, S., Bromley, M., Roberts, S., Patterson, A., Hunter, R., Stratford, I. and West, C. (2001): Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res, 7:928?34.
  19. Cattoretti, G., Becker, M., Key, G., Duchrow, M., Schl?ter, C., Galle, J. and Gerdes, J. (1992): Monoclonal antibodies against recombinant parts of the Ki67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin fixed paraffin sections. J Pathol : 168: 357-363.
  20. Page, C.L., Huntsman, C.L., Provencher, D.G, and Mes-Masson, A.M. (2010): Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies. Cancers. 2: 913-954.
  21. Reitmaier, M., Rudlowski, C., Biesterfeld, S., Rath, W. and Schroder, W. (2000): Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma. Zentralbl. Gynakol, 122: 361?367.
  22. Schonborn, I., Minguillon, C., Mohner, M. and Ebeling, K. (1993): Importance of PCNA proliferating fraction and histomorphologic prognostic factors for survival in breast cancer. Pathologe, 14: 307?312.
  23. H?hn, A.K., Einenkel, J., Wittekind, C. and Horn, L.C. (2014):New FIGO classification of ovarian, fallopian tube and primary peritoneal cancer. 35(4):322-6.
  24. Semaan, A., Munkarah, A., Arabi, H., Bandyopadhyay, S., Seward, S., Kumar, S., Qazi, A, Hussein, Y,, Morris, R.T. and Ali-Fehmi, R. (2011): Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation,angiogenesis,survival and ability to predict optimal cytoreduction Gynecol Oncol:121(1):181?186.
  25. Yasuda, M., Miyazawa, M., Fujita, M., Kajiwara, H., Iida, T., Hirasawa, T., Muramatsu, T., Murakami, M., Mikami, M., Saitoh, K., Shimizu, M., Takekoshi, S. and Osamura, R. Y. (2008): Expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1(GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status dependingon histological character. Oncol Rep, 19:111?6.
  26. Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R., Angioli, R., Penalver, M., Mancuso, S. and Scambia, G. (2001): GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer, 92:1144?50.
  27. Theile, A. and Mueller, K.M. (1996): Proliferation kinetics of brochioloalveolar tumorlets. Pathologe, 17(2):163?70.
  28. Cho, H., Lee, Y. and Kim J. (2013): Overexpression of Glucose Transporter-1(GLUT-1) Predicts Poor Prognosis in Epithelial Ovarian Cancer, Cancer Investigation, 31:607?615.
  29. Overexpression of Glucose Transporter-1(GLUT-1) Predicts Poor Prognosis in Epithelial Ovarian Cancer, Cancer Investigation, 31:607?615
  30. Yokoyama, Y., Jones, C., Licence, A.,Yanaihara, A.,?Hastings,J.M., Holland, C.M.,?Emoto, M., Umemoto, M.,?Sakamoto, T.,?Sato, S., Mizunuma,H.,and Smith, SK., (2003): Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. British Journal of Cancer. 88: 237?244.
  31. Sundov, D., Caric, A., Mrklic, I., Gugic, D., Capkun, V., Hofman, I.D., Mise B.P., and Tomic, S. (2013): P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas. Diagnostic Pathology, 8:21
  32. Wang, L., Li, H., Wen, J., and Peng S. (2014): Expression of CD44v3, erythropoietin and VEGF-C in gastric adenocarcinomas: correlations with clinicopathological features. Clinica Chimica Acta., 100 (3): 321-327.
  33. Skirnisdottir I., Seidal T. and ?kerud H. (2016): The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I-II. Int J Oncol., 48(3): 998?1006.
  34. Kalir, T., Wang, B., Goldfischer, M., Haber, R.S., Reder, I., Demopoulos, R., Cohen, C.J. and Burstein, D.E. (2002): Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. Cancer. 94: 1078?1082.
  35. Ma, X., Hui, Y., Lin, L., Wu, Y., Zhang, X. and Liu, P.(2015): Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues. Pak J Med Sci, 31(2):280-284.
  36. Iida T., Yasuda M., Miyazawa M., Fujita, M., Hirasawa, T., Muramatsu, T., Murakami, M., Saito, K. and Mikami, M. (2008): Hypoxic status in ovarian serous and mucinous tumors, relationship between histological characteristics and HIF-1/GLUT-1 expression. Arch Gynecol Obstet, 277:539?546.
  37. Zhao, S.J., Liu, J.Y., Ren, F.R. and Feng, Y.J.(2005) Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm. Zhonghua Fu Chan Ke Za Zhi, 40(4):264-8.
  38. Kim, K., Park, W., Kim, J., Sol, M.Y., Shin, D, H., Park, D, Y., Lee, C.H., Lee, J.H. and Choi, K.U. (2012): Prognostic Relevance of the Expression of CA IX, GLUT-1, and VEGF in Ovarian Epithelial Cancers. Korean J Pathol Pathol, 46(6):532?540.
  39. Mamede, M., Higashi, T., Kitaichiy, M., Ishizu, K., Ishimori, T., Nakamoto, Y., Yanagiharaz, K., Li z, M., Tanakaz, F., Wadaz, H., Manabey, T. and Saga, T. (2005): FDG Uptake and PCNA, Glut-1, and Hexokinase-II Expressions in Cancers and Inflammatory Lesions of the Lung. Neoplasia, 7:(4) 369 ? 379.

[Samah S. Elbasateeny, Mai M. Abdelwahab, Mohamed A.Ibrahem and Ibtsam S. Harera. (2017); IMMUNOHISTOCHEMICAL EXPRESSION OF GLUT-1 IN EPITHELIAL OVARIAN TUMORS: CORRELATION WITH THE CLINICOPATHOLOGICAL FACTORS AND TUMOR PROLIFERATIVE MARKER PCNA. Int. J. of Adv. Res. 5 (1). 789-800] (ISSN 2320-5407). www.journalijar.com


Samah Said Elbasateeny
Pathology Department, Faculty of medicine, Zagazig University, Egypt

DOI:


Article DOI: 10.21474/IJAR01/2815       DOI URL: http://dx.doi.org/10.21474/IJAR01/2815


Share this article